ReviewInternational journal of molecular sciences2026
The Future of Breast Cancer Treatment: From Conventional Wisdom to Nanotechnology-Enabled Precision.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hypoxia-induced mechanism of TNBC promoting tumour cell proliferation through exosomal miRNA.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Targeting CDK8 dually enhances paclitaxel antitumor efficacy and alleviates chemotherapy-induced peripheral neuropathy in breast cancer.Frontiers in pharmacology · 2026Article
- Editorial: Innovative therapeutic approaches for complex cancers: exploring new strategies.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading cause of mortality among women worldwide, presenting significant treatment challenges due to its aggressive nature and lack of targeted therapies. Traditional treatments, including surgery, radiation, and chemotherapy, have improved survival rates. However, limitations such as drug resistance and adverse side effects persist. Recent advancements in nanotechnology offer promising avenues for enhancing breast cancer treatment by improving drug delivery, increasing therapeutic efficacy, and minimizing systemic toxicity. This review explores breast cancer's pathophysiology and molecular mechanisms, evaluates current diagnostic and therapeutic strategies, and discusses emerging innovations in nanotechnology and integrative medicine. Recent studies have demonstrated the efficacy of green nanotechnology in transforming Ayurvedic medicine into scientifically credible treatments. These integrative approaches not only enhance the therapeutic potential of traditional medicine but also offer a pathway to overcome challenges associated with conventional cancer treatments. The convergence of nanotechnology and traditional medical systems holds transformative potential in breast cancer therapy. By leveraging the unique properties of nanoparticles and nanorobotics, it is possible to develop more effective, personalized, and less toxic treatment modalities. Future research should optimize these integrative approaches, conduct rigorous clinical trials, and elucidate the underlying mechanisms to fully realize their potential in combating breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.